Yue Zhang

The paper identifies synthetic dosage lethality targets for PLK1-overexpressing cancers using genome-wide screens and validates key hits to show their therapeutic potential.

This study identifies Neurog2 as a potential therapeutic target for MYCN-driven neuroendocrine prostate cancer by showing its role in promoting tumor growth and NEPC development.

The paper identifies FTSJ3 as a critical vulnerability in hTERT-overexpressing cancers by showing its role in TERRA methylation and telomeric heterochromatin stability.

This study examines intratumor heterogeneity and evolution patterns in colorectal cancer, finding a Darwinian pattern with differences between right-sided and left-sided tumors.